As an example of the rapidly growing interest in this technology platform, Pfizer Inc just recently announced a Request for Proposals (RFP) to develop such qEEG markers in AD, attention deficit– hyperactivity disorder, and schizophrenia (www.pfizer.com/translationalmedicine).